Русский
Current trends in bladder cancer diagnosis
DOI: https://dx.doi.org/10.18565/urology.2018.5.100-105
A.I. Glukhov, N.V. Polotdykova, S.A. Gordeev, A.Z. Vinarov, K.A. Polyakovsky, L.M. Rapoport, D.G. Tsarichenko, D.V. Enikeev, P.V. Glybochko
1 I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University), Moscow, Russia; 2 Department of Biochemistry of Sechenov First Moscow State Medical University of the Ministry of Health of Russia, Moscow, Russia; 3 M.V. Lomonosov Moscow State University, Faculty of Biology, Moscow, Russia; 4 University Clinical hospital №2 of I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University), Moscow, Russia
In the Russian Federation, a proportion of bladder cancer in the overall structure of malignant tumors is about 2.8% and among oncological diseases of genitourinary system its incidence is second only to prostate cancer. Bladder cancer ranks as ninth most prevalent in males and as eighteens in females. The most important issue is to determine a recurrence rate of non-muscle invasive bladder cancer, which can reach 80%. In this regard, currently, all over the world much more attention is paid to studying and creation of early detection, including non-invasive, which will be reliable in the early stages. It can possibly lead to a reduction the number of cystoscopy and become as “golden” standard of non-invasive diagnosis bladder cancer.
Keywords: urinary bladder cancer, telomerase, urinary bladder, non-invasive diagnosis
About the Autors
Corresponding author: N.V. Polotdykova – junior researcher at the Scientific Research Institute of Uronephrology and Reproductive Health, Urologic Department and Clinic of I.M. Sechenov First Moscow State Medical University, Moscow, Russia; e-mail: natalis8282@mail.ru
